nach oben

Langenbeck's Archives of Surgery

Erschienen in:

28.07.2017 | REVIEW ARTICLE

Bridging to liver transplantation in HCC patients

verfasst von: Dagmar Kollmann, Nazia Selzner, Markus Selzner

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Liver transplantation (LT) is the only cure for patients diagnosed with unresectable hepatocellular carcinoma (HCC), and HCC has become the leading indication for LT in the USA. The shortage of liver grafts results in a significant waiting time for LT with the risk of tumour progression. Treating HCCs during the waiting time prior to transplantation (bridging therapy) is an attractive strategy to reduce the risk of exceeding the tumour criteria for transplantation. Studies on bridging therapy are heterogenous and due to ethical issues, mostly of retrospective design.

Purpose

We summarize the main studies and methods that have been reported on bridging therapies for patients with HCC waiting for a LT.

Conclusion

During the waiting period for LT, patients with HCC at risk for tumour progression and therefore bridging therapy is recommended for patients with an estimated waiting time of ≥6 months. Bridging therapy for patients with HCC prior to LT mainly include locoregional therapies (LRTs), with transarterial chemoembolization (TACE) being the most common, followed by radio frequency ablation (RFA). Because of a continuous enhancement of therapy options, including a more precise adjustment of external radiotherapy, further possibilities for an individualized bridging therapy for patients with HCC have been developed. Patients with compensated liver cirrhosis and small tumour size are preferably treated with RFA, whereas patients with larger tumour size but compensated liver function are treated with TACE/TARE. Patients with uncompensated liver cirrhosis and larger tumour size can nowadays be successfully bridged to LT with external radiotherapy without increasing the risk for further deterioration of liver function.

Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781PubMedCrossRef

Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M et al (2017) Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67(2):302–309

Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ et al (2017) Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol 15(5):767–775 e3PubMedCrossRef

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef

UNOS. UNOS. Available from: URL: http://www.unos.org. Category Newsdata

Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608PubMedCrossRef

Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11):2587–2596PubMedCrossRef

Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A et al (2016) The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 64(6):2077–2088PubMedCrossRef

Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P et al (2011) Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transpl 25(5):E541–E551CrossRef

10.

Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N et al (2014) Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 97(2):220–226PubMedCrossRef

11.

Bruix J, Sherman M (2011) American Association for the Study of liver D. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedPubMedCentralCrossRef

12.

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255PubMedCrossRef

13.

Bhardwaj N, Perera MT, Silva MA (2016) Current treatment approaches to HCC with a special consideration to transplantation. J Transp Secur 2016:7926264

14.

European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef

15.

Young AL, Adair R, Prasad KR, Toogood GJ, Lodge JP (2012) Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. J Am Coll Surg 214(2):174–183PubMedCrossRef

16.

Yeh CN, Lee WC, Chen MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang gung memorial hospital. Ann Surg Oncol 10(9):1070–1076PubMedCrossRef

17.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699PubMedCrossRef

18.

Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440PubMedCrossRef

19.

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35(3):421–430PubMedCrossRef

20.

Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A et al (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22PubMedCrossRef

21.

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403PubMedCrossRef

22.

Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W et al (2012) Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol 2012:253517PubMedPubMedCentralCrossRef

23.

Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA et al (2001) Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 7(7):631–636PubMedCrossRef

24.

DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS et al (2011) Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 253(1):166–172PubMedCrossRef

25.

Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10(1):35–43PubMedCrossRef

26.

Grat M, Wronka KM, Stypulkowski J, Bik E, Krasnodebski M, Masior L et al (2017) The Warsaw proposal for the use of extended selection criteria in liver transplantation for hepatocellular cancer. Ann Surg Oncol 24(2):526–534PubMedCrossRef

27.

Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J et al (2008) Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 14(8):1107–1115PubMedCrossRef

28.

Freeman RB, Edwards EB, Harper AM (2006) Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 6(6):1416–1421PubMedCrossRef

29.

Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR et al (2007) An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol 14(9):2608–2614PubMedCrossRef

30.

Baccarani U, Isola M, Adani GL, Benzoni E, Avellini C, Lorenzin D et al (2008) Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int 21(3):247–254PubMedCrossRef

31.

Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY (2013) Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 19(12):1343–1353PubMedCrossRef

32.

Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM (2008) Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 8(4 Pt 2):958–976PubMedCrossRef

33.

Xing M, Kim HS (2017) Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med 6(1):26–35PubMedCrossRef

34.

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver IntLiver Int 35(9):2155–2166CrossRef

35.

Oligane HC, Close ON, Xing M, Kim HS (2017) Bridging locoregional therapy: longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev (Orlando)

36.

Magnetta MJ, Xing M, Zhang D, Kim HS (2016) The effect of bridging locoregional therapy and Sociodemographics on survival in hepatocellular carcinoma patients undergoing orthotopic liver transplantation: a united network for organ sharing population study. J Vasc Interv Radioll 27(12):1822–1828CrossRef

37.

Hoehn RS, Hanseman DJ, Wima K, Ertel AE, Paquette IM, Abbott DE et al (2015) Does race affect management and survival in hepatocellular carcinoma in the United States? Surgery 158(5):1244–1251PubMedCrossRef

38.

Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ (2015) Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer 4(1):70–83PubMedPubMedCentralCrossRef

39.

Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V et al (2010) Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer 116(7):1801–1809PubMedPubMedCentralCrossRef

40.

Zak Y, Rhoads KF, Visser BC (2011) Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg 146(7):778–784PubMedCrossRef

41.

Fujiki M, Aucejo F, Choi M, Kim R (2014) Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol 20(18):5308–5319PubMedPubMedCentralCrossRef

42.

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442PubMedCrossRef

43.

Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA (2006) Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 6(11):2644–2650PubMedCrossRef

44.

Li H, Li B, Wei Y, Yan L, Wen T, Wang W et al (2015) Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: a single center 12-year experience. Clin Res Hepatol Gastroenterol 39(4):451–457PubMedCrossRef

45.

Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF et al (2006) Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 12(4):665–673PubMedCrossRef

46.

Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J et al (2017) Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a ten year intention-to-treat analysis. Hepatology

47.

Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R et al (2017) Stereotactic body radiotherapy versus TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol

48.

Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A et al (2010) Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 23(3):299–306PubMedCrossRef

49.

Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R et al (2007) Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 13(2):272–279PubMedCrossRef

50.

Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41(5):1130–1137PubMedCrossRef

51.

Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M et al (2004) Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 4(5):782–787PubMedCrossRef

52.

Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK et al (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449–455PubMedCrossRef

53.

Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transp 9(6):557–563CrossRef

54.

Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC et al (2012) Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria. Transplant Proc 44(2):403–408PubMedCrossRef

55.

Manini MA, Sangiovanni A, Martinetti L, Vigano D, La Mura V, Aghemo A et al (2015) Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl 21(10):1259–1269PubMedCrossRef

56.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCrossRef

57.

Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D et al (2013) Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 58(1):73–80PubMedCrossRef

58.

Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D et al (2014) Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 60(1):192–201PubMedCrossRef

59.

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(6):1155–1163 e2 PubMedCrossRef

60.

Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1):82–89PubMedCrossRef

61.

Facciorusso A, Serviddio G, Muscatiello N (2016) Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther 7(4):477–489PubMedPubMedCentralCrossRef

62.

Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P et al (2014) The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol 21(3):e480–e492PubMedPubMedCentralCrossRef

63.

Koffron AJ, Auffenberg G, Kung R, Abecassis M (2007) Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 246(3):385–392 discussion 92-4 PubMedPubMedCentralCrossRef

64.

Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514–524PubMedCrossRef

65.

Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R et al (2003) Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 14(10):1267–1274PubMedCrossRef

66.

Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R et al (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240(5):900–909PubMedPubMedCentralCrossRef

67.

Agopian VG, Morshedi MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinpar A et al (2015) Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg 262(3):536–545 discussion 43-5 PubMedCrossRef

68.

Vasnani R, Ginsburg M, Ahmed O, Doshi T, Hart J, Te H et al (2016) Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation. Hepatobiliary Surg Nutr 5(3):225–233PubMedPubMedCentralCrossRef

69.

Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S et al (2005) Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 11(9):1117–1126PubMedCrossRef

70.

Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J et al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81(4):e447–e453PubMedCrossRef

71.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34PubMedCrossRef

72.

Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P et al (2010) Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51(1):165–173PubMedCrossRef

73.

Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I et al (2008) Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349PubMedPubMedCentralCrossRef

74.

Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O et al (2015) Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients—a prospective, randomized, double-blind, phase III trial. BMC Cancer 15:392PubMedPubMedCentralCrossRef

75.

Cescon M, Cucchetti A, Ravaioli M, Pinna AD (2013) Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 58(3):609–618PubMedCrossRef

76.

Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K et al (2012) Loco-regional therapy in patients with Milan criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. HPB (Oxford) 14(5):325–332CrossRef

77.

Crocetti L, de Baere T, Lencioni R (2010) Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 33(1):11–17PubMedCrossRef

78.

Lencioni R, Petruzzi P, Crocetti L (2013) Chemoembolization of hepatocellular carcinoma. Semin Interv Radiol 30(1):3–11CrossRef

79.

Mosconi C, Cappelli A, Pettinato C, Golfieri R (2015) Radioembolization with yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol 7(5):738–752PubMedPubMedCentralCrossRef

80.

Rim CH, Seong J (2016) Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J 34(3):160–167PubMedPubMedCentralCrossRef

81.

Sanuki N, Takeda A, Kunieda E (2014) Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 20(12):3100–3111PubMedPubMedCentralCrossRef

Titel: Bridging to liver transplantation in HCC patients
verfasst von: Dagmar Kollmann
Nazia Selzner
Markus Selzner
Publikationsdatum: 28.07.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Langenbeck's Archives of Surgery / Ausgabe 6/2017
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-017-1609-2

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Purpose

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Acute appendicitis in children: can surgery be postponed? Short-term results in a cohort of 225 children?

Prevention of parastomal hernia in the emergency setting

Linear stapled gastrojejunostomy results in fewer strictures compared to circular stapled gastrojejunostomy in laparoscopic gastric bypass surgery

Outcomes after bariatric surgery according to large databases: a systematic review

Contribution of intraoperative neural monitoring to preservation of the external branch of the superior laryngeal nerve: a randomized prospective clinical trial

Gastric bypass simultaneously improves adipose tissue function and insulin-dependent type 2 diabetes mellitus

Update Chirurgie